Wells Fargo analyst Mohit Bansal upgraded Jazz Pharmaceuticals (JAZZ) to Overweight from Equal Weight with a price target of $170, up from ...
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Crispr Therapeutics AG (CRSP – Research Report), Jazz ...
Fintel reports that on February 13, 2025, Wells Fargo upgraded their outlook for Jazz Pharmaceuticals (NasdaqGS:JAZZ) from Equal-Weight to Overweight. As of January 28, 2025, the average one-year ...
Learn how you can get involved today and use the hashtag #UnitedByUnique Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of ...
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for ...
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for ...
Fintel reports that on February 13, 2025, Wells Fargo upgraded their outlook for Jazz Pharmaceuticals (BRSE:J7Z) from Equal-Weight to Overweight. There are 1,018 funds or institutions reporting ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback